Cargando…
Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
The need for efficacious and non-toxic cancer therapies is paramount. Oncolytic viruses (OVs) are showing great promise and are introducing new possibilities in cancer treatment with their ability to selectively infect tumor cells and trigger antitumor immune responses. Herpes Simplex Virus 1 (HSV-1...
Autores principales: | Scanlan, Hayle, Coffman, Zachary, Bettencourt, Jeffrey, Shipley, Timothy, Bramblett, Debra E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364694/ https://www.ncbi.nlm.nih.gov/pubmed/35965554 http://dx.doi.org/10.3389/fonc.2022.940019 |
Ejemplares similares
-
Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017) -
Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018) -
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021) -
Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016) -
Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis
por: Ghouse, Shanawaz M., et al.
Publicado: (2020)